Transaction overview
Infinity Behavioral Health Services (US) acquired Health Assets Management, Inc. (US) on November 30, 2017. While the specific deal value was not disclosed, the acquisition aimed to expand Infinity's service offerings in the behavioral health sector by integrating Health Assets' revenue cycle management capabilities into its existing portfolio.
Deal structure and financing
The exact equity and debt split for this transaction is unknown, as no financial details were publicly disclosed. No information is available on the lead banks involved or leverage metrics applied. It is unclear whether the seller retained any stake in Infinity Behavioral Health Services post-acquisition. Additionally, lock-up terms and potential IPO optionality are not specified.
Strategic context
The acquisition of Health Assets Management by Infinity Behavioral Health Services was driven by the need to strengthen its service offerings within the behavioral health revenue cycle management sector. This strategic move allows Infinity to broaden its portfolio and enhance its ability to serve clients across various stages of the revenue cycle continuum, from front-end services such as verification of benefits and utilization review to back-end billing and collections.
Health Assets Management was likely divested by a private equity firm seeking an exit following a period of growth under ownership. The acquisition fits into Infinity's broader strategy of expanding its service capabilities since 2015 when Thompson Street Capital Partners acquired the company. Prior acquisitions, such as those of Hyperion Billing Solutions and Health Assets Management itself, have been integral to building Infinity’s position in the behavioral health revenue cycle management space.
Regulatory path
No specific regulatory details were disclosed regarding this transaction, including any filings with antitrust authorities or reviews by relevant agencies. Given the nature of the healthcare sector and the geographic focus on the United States, it is likely that the deal was reviewed under U.S. antitrust laws, potentially involving filings with the Federal Trade Commission (FTC) or the Department of Justice (DOJ). However, without specific details, the exact regulatory path taken remains unclear.